Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $4.87

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.76, but opened at $4.87. Lexicon Pharmaceuticals shares last traded at $4.98, with a volume of 2,555,257 shares changing hands.

Several equities research analysts recently weighed in on LXRX shares. G.Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. Citigroup downgraded Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their target price for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $6.45.

The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The firm has a market cap of $523.91 million, a PE ratio of -4.37 and a beta of 1.00. The stock has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $3.84.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.80. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same quarter last year, the firm posted ($0.26) EPS. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post 0.93 EPS for the current fiscal year.

In other news, Director Christopher J. Sobecki purchased 99,249 shares of the stock in a transaction dated Friday, September 13th. The shares were purchased at an average cost of $2.41 per share, with a total value of $239,190.09. Following the acquisition, the director now directly owns 13,645 shares of the company’s stock, valued at $32,884.45. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher J. Sobecki purchased 25,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was purchased at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares in the company, valued at $286,857.15. The disclosure for this purchase can be found here. Insiders have bought 178,749 shares of company stock valued at $474,560 over the last three months. 6.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new position in Lexicon Pharmaceuticals in the second quarter worth about $92,000. Commonwealth Equity Services LLC lifted its stake in shares of Lexicon Pharmaceuticals by 40.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 4,746 shares during the period. Voloridge Investment Management LLC bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $105,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Lexicon Pharmaceuticals by 77.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 26,900 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter worth approximately $202,000. Institutional investors own 96.27% of the company’s stock.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: Percentage Gainers

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.